Cited by 667Diabetes Management and ResearchDiabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

Insulin Analogues

Hirsch, Irl B.·2005·New England Journal of Medicine

DOI 10.1056/nejmra040832

Open this paper in CoChat — free account

Abstract

In the 1990s, the value of glycemic control in the management of diabetes became incontrovertible. The interest in producing insulin formulations that are safer than previous formulations and that more closely duplicate the basal and mealtime components of endogenous insulin secretion has yielded insulin analogues with action profiles that afford more flexible treatment regimens and a lower risk of hypoglycemia. This article examines the use of these newer insulins in clinical practice.

Integrity signals

Registry

Crossref · 10.1056/nejmra040832

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
(1998) · The Lancet · doi:10.1016/s0140-6736(98)07019-6 · Cited by 20,023
Untitled work
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
Lepore, M., Pampanelli, S., Fanelli, C., Porcellati, F., Bartocci, L., Di Vincenzo, A., Cordoni, C., Costa, E., Brunetti, P., & Bolli, G. B. (2000) · Diabetes · doi:10.2337/diabetes.49.12.2142 · Cited by 818
Intermittent High Glucose Enhances Apoptosis Related to Oxidative Stress in Human Umbilical Vein Endothelial Cells
Quagliaro, L., Piconi, L., Assaloni, R., Martinelli, L., Motz, E., & Ceriello, A. (2003) · Diabetes · doi:10.2337/diabetes.52.11.2795 · Cited by 772
Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use
Kurtzhals, P., Schäffer, L., Sørensen, A., Kristensen, C., Jonassen, I., Schmid, C., & Trüb, T. (2000) · Diabetes · doi:10.2337/diabetes.49.6.999 · Cited by 739
Standards of Medical Care in Diabetes
(2004) · Diabetes Care · doi:10.2337/diacare.27.2007.s15 · Cited by 688
Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.
Yki‐Järvinen, H., Dressler, A., Ziemen, M., & HOE 901/300s Study Group (2000) · Diabetes Care · doi:10.2337/diacare.23.8.1130 · Cited by 573
Outpatient Insulin Therapy in Type 1 and Type 2 Diabetes Mellitus: Scientific Review
DeWitt, D. E., & Hirsch, I. B. (2003) · JAMA · doi:10.1001/jama.289.17.2254 · Cited by 502
Self-citation
Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus
Ward, W. K., Bolgiano, D. C., McKnight, B., Halter, J. B., & Porte, D. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111542 · Cited by 483

Flagged first, then by citations

Show all 62 references

Sorted by citations

Items 101–200 of 667

Evolution of Insulin Development: Focus on Key Parameters
Tibaldi, J. M. (2012) · Advances in Therapy · doi:10.1007/s12325-012-0034-8 · Cited by 64
Steady‐state pharmacokinetics and glucodynamics of the novel, long‐acting basal insulin LY2605541 dosed once‐daily in patients with type 2 diabetes mellitus
Sinha, V. P., Howey, D. C., Choi, S. L., Mace, K. F., & Heise, T. (2013) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12222 · Cited by 60
Opportunities and Challenges for Biosimilars: What's on the Horizon in the Global Insulin Market?
Rotenstein, L. S., Ran, N. A., Shivers, J. P., Yarchoan, M. M., & Close, K. L. (2012) · Clinical Diabetes · doi:10.2337/diaclin.30.4.138 · Cited by 61
Treatment of diabetes mellitus using an external insulin pump: the state of the art
Hanaire, H. P., Lassmann-Vague, V., Jeandidier, N., Renard, É., Tubiana‐Rufi, N., Vambergue, A., Raccah, D., Pinget, M., & Guerci, B. (2008) · Diabetes & Metabolism · doi:10.1016/s1262-3636(08)73972-7 · Cited by 64
Treatment of Type 1 Diabetes: Synopsis of the 2017 American Diabetes Association Standards of Medical Care in Diabetes
Chamberlain, J. J., Kalyani, R. R., Leal, S., Rhinehart, A. S., Shubrook, J. H., SKOLNIK, N., & Herman, W. H. (2017) · Annals of Internal Medicine · doi:10.7326/m17-1259 · Cited by 63
Disorders of glucose metabolism–post mortem analyses in forensic cases: part I
Heß, C., Mußhoff, F., & Madea, B. (2010) · International Journal of Legal Medicine · doi:10.1007/s00414-010-0509-6 · Cited by 63
Comparative Pharmacokinetics and Insulin Action for Three Rapid-Acting Insulin Analogs Injected Subcutaneously With and Without Hyaluronidase
Morrow, L., Muchmore, D. B., Hompesch, M., Ludington, E. A., & Vaughn, D. E. (2012) · Diabetes Care · doi:10.2337/dc12-0808 · Cited by 60
Short-acting insulin analogues versus regular human insulin on postprandial glucose and hypoglycemia in type 1 diabetes mellitus: a systematic review and meta-analysis
Melo, K., Bahia, L., Pasinato, B. P. R., Porfírio, G. J. M., Martimbianco, A. L. C., Riera, R., Calliari, L. E., Minicucci, W. J., Turatti, L. A. A., Pedrosa, H. C., et al. (2019) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-018-0397-3 · Cited by 61
New Approaches to Providing Individualized Diabetes Care in the 21st Century
Powell, P. W., Corathers, S. D., Raymond, J. K., & Streisand, R. M. (2015) · Current Diabetes Reviews · doi:10.2174/1573399811666150421110316 · Cited by 60
Insulin analogs for the treatment of diabetes mellitus: therapeutic applications of protein engineering
Berenson, D. F., Weiss, A. R., Wan, Z., & Weiss, M. A. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2012.06468.x · Cited by 60
Insulin-Related Knowledge Among Health Care Professionals in Internal Medicine
Derr, R. L., Sivanandy, M. S., Bronich-Hall, L., & Rodríguez, A. (2007) · Diabetes Spectrum · doi:10.2337/diaspect.20.3.177 · Cited by 59
Insulin management of type 2 diabetes mellitus.
Petznick, A. M. (2011) · PubMed · doi:10.1016/s0002-838x(11)60220-7 · Cited by 58
Supramolecular insulin assembly II for a sustained treatment of type 1 diabetes mellitus
Gupta, S., Chattopadhyay, T., Singh, M. P., & Surolia, A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005704107 · Cited by 58
Multicentre, randomised, controlled study of the impact of continuous sub-cutaneous glucose monitoring (GlucoDay®) on glycaemic control in type 1 and type 2 diabetes patients
Cosson, E., Hamo-Tchatchouang, E., Dufaitre-Patouraux, L., Attali, J.-R., Pariès, J., & Schaepelynck-Bélicar, P. (2009) · Diabetes & Metabolism · doi:10.1016/j.diabet.2009.02.006 · Cited by 57
Inhaled Technosphere® Insulin in Comparison to Subcutaneous Regular Human Insulin: Time Action Profile and Variability in Subjects with Type 2 Diabetes
Rave, K., Heise, T., Heinemann, L., & Boss, A. (2008) · Journal of Diabetes Science and Technology · doi:10.1177/193229680800200206 · Cited by 57
Insulin therapy and its consequences for the mother, foetus, and newborn in gestational diabetes mellitus
Subiabre, M., Silva, L., Toledo, F., Mario Paublo, M., López, M. A., Borić, M. P., & Sobrevía, L. (2018) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2018.06.005 · Cited by 59
Addressing Cultural Barriers to the Successful Use of Insulin in Hispanics with Type 2 Diabetes
Campos, C. (2007) · Southern Medical Journal · doi:10.1097/smj.0b013e3180f609c4 · Cited by 56
New-Onset Diabetes Mellitus in the Kidney Recipient
Bloom, R. D., & Crutchlow, M. F. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.02650707 · Cited by 59
Assessment of adherence and healthcare costs of insulin device (FlexPen®) versus conventional vial/syringe
Başer, O., Bouchard, J. R., DeLuzio, T., Henk, H. J., & Aagren, M. (2010) · Advances in Therapy · doi:10.1007/s12325-010-0009-6 · Cited by 56
Noninvasive Insulin Delivery: the Great Potential of cell-penetrating Peptides
Kamei, N., Nielsen, E. J. B., Khafagy, E., & Takeda‐Morishita, M. (2013) · Therapeutic Delivery · doi:10.4155/tde.12.164 · Cited by 57
Dose-Dependent Delay of the Hypoglycemic Effect of Short-Acting Insulin Analogs in Obese Subjects With Type 2 Diabetes
Gagnon‐Auger, M., du Souich, P., Baillargeon, J., Martin, É., Brassard, P., Ménard, J., & Ardilouze, J. (2010) · Diabetes Care · doi:10.2337/dc10-1126 · Cited by 56
Glargine vs. NPH insulin therapy in pregnancies complicated by diabetes: an observational cohort study
Negrato, C. A., Rafacho, A., Negrato, G., Teixeira, M. F., Araújo, C. A. R., Vieira, L., Silva, C. A., Date, S. K., Demarchi, A. C., & Gomes, M. B. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.03.015 · Cited by 55
Pharmacokinetics and Glucodynamics of Ultra Rapid Lispro (URLi) versus Humalog® (Lispro) in Younger Adults and Elderly Patients with Type 1 Diabetes Mellitus: A Randomised Controlled Trial
Linnebjerg, H., Zhang, Q., LaBell, E. S., Dellva, M. A., Coutant, D. E., Hövelmann, U., Plum‐Mörschel, L., Herbrand, T., & Leohr, J. K. (2020) · Clinical Pharmacokinetics · doi:10.1007/s40262-020-00903-0 · Cited by 59
Protein conformational changes induced by adsorption onto material surfaces: an important issue for biomedical applications of material science
Ballet, T., Boulangé, L., Brechet, Y. J. M., Brückert, F., & Weidenhaupt, M. (2010) · Bulletin of the Polish Academy of Sciences Technical Sciences · doi:10.2478/v10175-010-0028-0 · Cited by 53
Extensive study of human insulin immunoassays: promises and pitfalls for insulin analogue detection and quantification
Heurtault, B., Reix, N., Meyer, N., Gasser, F., Wendling, M.-J., Ratomponirina, C., Jeandidier, N., Sapin, R., & Agin, A. (2013) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2013-0427 · Cited by 54
Lower Risk of Hypoglycemia with Insulin Detemir than with Neutral Protamine Hagedorn Insulin in Older Persons with Type 2 Diabetes: A Pooled Analysis of Phase III Trials
Garber, A. J., Clauson, P., Pedersen, C. B., & Kølendorf, K. (2007) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2007.01414.x · Cited by 53
The importance of synthetic drugs for type 2 diabetes drug discovery
Safavi, M., Foroumadi, A., & Abdollahi, M. R. (2013) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2013.837883 · Cited by 52
Gestational Diabetes Mellitus:current knowledge and unmet needs
Koning, S. H., Hoogenberg, K., Lutgers, H. L., van den Berg, P. P., & Wolffenbuttel, B. H. R. (2016) · Journal of Diabetes · doi:10.1111/1753-0407.12422 · Cited by 52
Emerging Nano- and Micro-Technologies Used in the Treatment of Type-1 Diabetes
Primavera, R., Kevadiya, B. D., Swaminathan, G., Wilson, R. J., Pascale, A. D., Decuzzi, P., & Thakor, A. S. (2020) · Nanomaterials · doi:10.3390/nano10040789 · Cited by 52
Initiating Insulin Therapy in Type 2 Diabetes: Benefits of Insulin Analogs and Insulin Pens
Brunton, S. (2008) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2008.0287 · Cited by 53
Treating type 1 diabetes: from strategies for insulin delivery to dual hormonal control.
McCall, A. L., & Farhy, L. S. (2013) · PubMed · Cited by 51
Use of insulin glargine during pregnancy
PÖYHÖNEN‐ALHO, M., RÖNNEMAA, T., SALTEVO, J., EKBLAD, U., & KAAJA, R. J. (2007) · Acta Obstetricia et Gynecologica Scandinavica · doi:10.1080/00016340701515282 · Cited by 52
Rational design of protamine nanocapsules as antigen delivery carriers
González-Aramúndiz, J. V., Presas, E., Dalmau‐Mena, I., Martínez-Pulgarín, S., Alonso, C., Escribano, J. M., Alonso, M. J., & Csaba, N. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2016.11.012 · Cited by 51
Basal Insulin Intensification in Patients with Type 2 Diabetes: A Review
Meece, J. D. (2018) · Diabetes Therapy · doi:10.1007/s13300-018-0395-3 · Cited by 51
Insulin Analogs and Cancer
Sciacca, L., Moli, R. L., & Vigneri, R. (2012) · Frontiers in Endocrinology · doi:10.3389/fendo.2012.00021 · Cited by 52
The Ideal Diabetes Therapy: What Will It Look Like? How Close Are We?
Rotenstein, L. S., Kozak, B. M., Shivers, J. P., Yarchoan, M. M., Close, J., & Close, K. L. (2012) · Clinical Diabetes · doi:10.2337/diaclin.30.2.44 · Cited by 50
Diabetes mellitus due to the toxic misfolding of proinsulin variants
Weiss, M. A. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.04.044 · Cited by 51
Treatment regimens with insulin analogues and haemoglobin A1c target of <7% in type 2 diabetes: A systematic review
Giugliano, D., Maiorino, M. I., Bellastella, G., Chiodini, P., & Esposito, K. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.08.006 · Cited by 48
Insulin Glargine: a review 8 years after its introduction
Goykhman, S., Drincic, A., Desmangles, J., & Rendell, M. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560902775677 · Cited by 49
New Strategies for Glucose Control in Patients With Type 1 and Type 2 Diabetes Mellitus in Pregnancy
Gabbe, S. G., Carpenter, L., & Garrison, E. (2007) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0b013e31815a6435 · Cited by 48
Intensification of Insulin Therapy for Type 2 Diabetic Patients in Primary Care: Basal-Bolus Regimen Versus Premix Insulin Analogs
Mosenzon, O., & Raz, I. (2013) · Diabetes Care · doi:10.2337/dcs13-2007 · Cited by 48
A Review on Bioengineering Approaches to Insulin Delivery: A Pharmaceutical and Engineering Perspective
Taraghdari, Z. B., Imani, R., & Mohabatpour, F. (2019) · Macromolecular Bioscience · doi:10.1002/mabi.201800458 · Cited by 47
Synthesis and Evaluation of Insulin−Human Serum Albumin Conjugates
Thibaudeau, K., Léger, R., Huang, X., Robitaille, M., Quraishi, O., Soucy, C., Bousquet-Gagnon, N., van Wyk, P., Paradis, V., Castaigne, J., et al. (2005) · Bioconjugate Chemistry · doi:10.1021/bc050102k · Cited by 47
Design of Non-Standard Insulin Analogs for the Treatment of Diabetes Mellitus
Pandyarajan, V., & Weiss, M. A. (2012) · Current Diabetes Reports · doi:10.1007/s11892-012-0318-z · Cited by 46
Insulin glargine compared with neutral protamine Hagedorn insulin in the treatment of pregnant diabetics
Victor Fang, Y. M., Mackeen, D., Egan, J. F. X., & Zelop, C. M. (2009) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767050802638170 · Cited by 45
The impact of chemical engineering and technological advances on managing diabetes: present and future concepts
Szunerits, S., Melinte, S., Barras, A., Pagneux, Q., Voronova, A., Abderrahmani, A., & Boukherroub, R. (2020) · Chemical Society Reviews · doi:10.1039/c9cs00886a · Cited by 47
Hypoglycemia Unawareness—A Review on Pathophysiology and Clinical Implications
Hölzen, L., Schultes, B., Meyhöfer, S. M., & Meyhöfer, S. (2024) · Biomedicines · doi:10.3390/biomedicines12020391 · Cited by 44
Insulins: Past, Present, and Future
Borgoño, C. A., & Zinman, B. (2012) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2012.03.002 · Cited by 48
Interventions for Diabetic Retinopathy in Type 1 Diabetes: Systematic Review and Meta-Analysis
Virk, S. A., Donaghue, K. C., Wong, T. Y., & Craig, M. E. (2015) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2015.07.024 · Cited by 45
Integrated Insulin Pump and Continuous Glucose Monitoring Technology in Diabetes Care Today: A Perspective of Real-Life Experience With the Minimed™ 670G Hybrid Closed-Loop System
Aleppo, G., & Webb, K. M. (2018) · Endocrine Practice · doi:10.4158/ep-2018-0097 · Cited by 45
Inhaled Technosphere Insulin versus inhaled technosphere placebo in insulin-naïve subjects with type 2 diabetes inadequately controlled on oral antidiabetes agents
Rosenstock, J., Franco, D., Korpachev, V., Shumel, B., Ma, Y., Baughman, R., Amin, N., McGill, J. B., & for the Affinity 2 Study Group (2015) · Diabetes Care · doi:10.2337/dc15-0629 · Cited by 43
Analytical and biosensing platforms for insulin: A review
Luong, A. D., Roy, I., Malhotra, B. D., & Luong, J. H. T. (2021) · Sensors and Actuators Reports · doi:10.1016/j.snr.2021.100028 · Cited by 44
Detection of Surreptitious Administration of Analog Insulin to an 8-Week-Old Infant
Green, R. P., Hollander, A., Thevis, M., Thomas, A., & Dietzen, D. J. (2010) · PEDIATRICS · doi:10.1542/peds.2009-2273 · Cited by 43
Practical approaches to insulin therapy for type 2 diabetes mellitus with premixed insulin analogues
Rolla, A. R., & Rakel, R. E. (2005) · Clinical Therapeutics · doi:10.1016/j.clinthera.2005.07.003 · Cited by 43
Reduced modeling of signal transduction – a modular approach
Koschorreck, M., Conzelmann, H., Ebert, S., Ederer, M., & Gilles, E. D. (2007) · BMC Bioinformatics · doi:10.1186/1471-2105-8-336 · Cited by 43
Treatment of diabetic ketoacidosis with subcutaneous insulin lispro: A review of the current evidence from clinical studies
Vincent, M., & Nobécourt, E. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2012.12.003 · Cited by 42
Solid-state Protein Formulations
Angkawinitwong, U., Sharma, G., Khaw, P. T., Brocchini, S., & Williams, G. R. (2015) · Therapeutic Delivery · doi:10.4155/tde.14.98 · Cited by 43
Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
Nasrallah, S. N., & Reynolds, L. R. (2012) · Clinical Medicine Insights Endocrinology and Diabetes · doi:10.4137/cmed.s9494 · Cited by 42
Insulin Fibrillation and Protein Design: Topological Resistance of Single-Chain Analogs to Thermal Degradation with Application to a Pump Reservoir
Phillips, N. B., Whittaker, J., Ismail‐Beigi, F., & Weiss, M. A. (2012) · Journal of Diabetes Science and Technology · doi:10.1177/193229681200600210 · Cited by 42
Dulaglutide for the treatment of type 2 diabetes
Scheen, A. J. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1296131 · Cited by 44
Patient empowerment and optimal glycemic control
White, R. D. (2012) · Current Medical Research and Opinion · doi:10.1185/03007995.2012.677417 · Cited by 41
Hypoglycemia in Insulin-Treated Diabetes: A Case for Increased Vigilance
Unger, J., & Parkin, C. G. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.07.2307 · Cited by 41
Allergic reactions to human insulin: a review of current knowledge and treatment options
Akıncı, B., Yener, S., Bayraktar, F., & Yeşil, S. (2009) · Endocrine · doi:10.1007/s12020-009-9256-1 · Cited by 40
Efficacy Determinants of Subcutaneous Microdose Glucagon during Closed-Loop Control
Russell, S. J., El-Khatib, F. H., Nathan, D. M., & Damiano, E. R. (2010) · Journal of Diabetes Science and Technology · doi:10.1177/193229681000400602 · Cited by 39
Basal insulin peglispro: Overview of a novel long‐acting insulin with reduced peripheral effect resulting in a hepato‐preferential action
Jacober, S. J., PRINCE, M. J., Beals, J. M., Hartman, M. L., Qu, Y., Linnebjerg, H., Garhyan, P., & Haupt, A. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12744 · Cited by 39
Closed-loop control with unannounced exercise for adults with type 1 diabetes using the Ensemble Model Predictive Control
Garcia‐Tirado, J., Corbett, J. P., Boiroux, D., Jørgensen, J. B., & Breton, M. D. (2019) · Journal of Process Control · doi:10.1016/j.jprocont.2019.05.017 · Cited by 40
Importance of Postprandial Glucose Levels as a Target for Glycemic Control in Type 2 Diabetes
Tibaldi, J. M. (2009) · Southern Medical Journal · doi:10.1097/smj.0b013e318188898e · Cited by 38
BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study
Heise, T., Meiffren, G., Alluis, B., Seroussi, C., Ranson, A., Arrubla, J., Correia, J., Gaudier, M., Soula, O., Soula, R., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13621 · Cited by 40
Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice
Goldman, J. D., Kapitza, C., Pettus, J., & Heise, T. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1335192 · Cited by 38
Insulin in motion: The A6-A11 disulfide bond allosterically modulates structural transitions required for insulin activity
van Lierop, B. J., Ong, S. C., Belgi, A., Delaine, C. A., Andrikopoulos, S., Haworth, N. L., Menting, J. G. T., Lawrence, M. C., Robinson, A. J., & Forbes, B. E. (2017) · Scientific Reports · doi:10.1038/s41598-017-16876-3 · Cited by 39
New and Emerging Technologies in Type 1 Diabetes
Sherwood, J. S., Russell, S. J., & Putman, M. S. (2020) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2020.07.006 · Cited by 46
Development of a POCT type insulin sensor employing anti-insulin single chain variable fragment based on faradaic electrochemical impedance spectroscopy under single frequency measurement
Khanwalker, M., Fujita, R., Lee, J., Wilson, E. D., Ito, K., Asano, R., Ikebukuro, K., Belle, J. T. L., & Sode, K. (2021) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2021.113901 · Cited by 40
Determination of hypoglycaemia induced by insulin or its synthetic analogues post mortem
Hess, C., Madea, B., Daldrup, T., & Mußhoff, F. (2013) · Drug Testing and Analysis · doi:10.1002/dta.1500 · Cited by 38
Chitosan–zinc–insulin complex incorporated thermosensitive polymer for controlled delivery of basal insulin in vivo
Oak, M., & Singh, J. (2012) · Journal of Controlled Release · doi:10.1016/j.jconrel.2012.07.035 · Cited by 38
Use of lispro insulin for treatment of diabetic ketoacidosis in dogs
Sears, K. W., Drobatz, K. J., & Hess, R. S. (2012) · Journal of Veterinary Emergency and Critical Care · doi:10.1111/j.1476-4431.2012.00719.x · Cited by 37
Initiation of insulin glargine in patients with Type 2 diabetes in suboptimal glycaemic control positively impacts health‐related quality of life. A prospective cohort study in primary care
Hajos, T. R. S., Pouwer, F., de Grooth, R., Holleman, F., Twisk, J. W. R., Diamant, M., & Snoek, F. J. (2011) · Diabetic Medicine · doi:10.1111/j.1464-5491.2011.03329.x · Cited by 37
Diabetes and Hyperglycemia in Lower-Extremity Total Joint Arthroplasty
Rudy, M. D., Ahuja, N. K., & Aaronson, A. J. (2018) · JBJS Reviews · doi:10.2106/jbjs.rvw.17.00146 · Cited by 38
Insulin Lispro
Simpson, D., McCormack, P. L., Keating, G. M., & Lyseng-Williamson, K. A. (2007) · Drugs · doi:10.2165/00003495-200767030-00006 · Cited by 37
Type 2 diabetes: A well-characterised but suboptimally controlled disease. Can we bridge the divide?
Monnier, L., Colette, C., & Owens, D. R. (2008) · Diabetes & Metabolism · doi:10.1016/j.diabet.2008.01.011 · Cited by 37
Ultra-Rapid Lispro Improves Postprandial Glucose Control and Time in Range in Type 1 Diabetes Compared to Lispro: PRONTO-T1D Continuous Glucose Monitoring Substudy
Małecki, M., Cao, D., Liu, R., Hardy, T., Bode, B., Bergenstal, R., & Bue-Valleskey, J. (2020) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2020.0129 · Cited by 30
Intensifying insulin therapy in patients with type 2 diabetes mellitus
Hirsch, I. B. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.04.011 · Cited by 37
Self-citation
Defining the Role of Insulin Detemir in Basal Insulin Therapy
Morales, J. (2007) · Drugs · doi:10.2165/00003495-200767170-00007 · Cited by 38
Long-acting insulin analogues elicit atypical signalling events mediated by the insulin receptor and insulin-like growth factor-I receptor
Yehezkel, E., Weinstein, D., Simon, M., Sarfstein, R., Laron, Z., & Werner, H. (2010) · Diabetologia · doi:10.1007/s00125-010-1899-1 · Cited by 36
Insulin glargine and receptor‐mediated signalling: clinical implications in treating type 2 diabetes
Roith, D. L. (2007) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.776 · Cited by 35
Mathematical modeling and analysis of insulin clearance in vivo
Koschorreck, M., & Gilles, E. D. (2008) · BMC Systems Biology · doi:10.1186/1752-0509-2-43 · Cited by 35
Relationship of baseline HbA1c, HbA1c change and HbA1c target of < 7% with insulin analogues in type 2 diabetes: a meta-analysis of randomised controlled trials
Giugliano, D., Maiorino, M. I., Bellastella, G., Chiodini, P., & Esposito, K. (2011) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2010.02619.x · Cited by 37
Clinical Experience with Insulin Glargine in Type 1 Diabetes
Garg, S. K., Moser, E. G., Dain, M., & Rodionova, A. S. (2010) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0135 · Cited by 35
Contemporary Management of Patients with Type 1 Diabetes
Mehta, S. N., & Wolfsdorf, J. I. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.05.002 · Cited by 35
Glycemic Variability in Type 2 Diabetes Mellitus
Johnson, E. L. (2012) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-5441-0_13 · Cited by 34
Insulin-like plant proteins as potential innovative drugs to treat diabetes—The Moringa oleifera case study
de Paula, P. C., Oliveira, J. T. A., Sousa, D. O. B., Alves, B. G. T., Carvalho, A. F. U., Franco, O. L., & Vasconcelos, I. M. (2016) · New Biotechnology · doi:10.1016/j.nbt.2016.10.005 · Cited by 35
Is Subcutaneous Administration of Rapid-Acting Insulin as Effective as Intravenous Insulin for Treating Diabetic Ketoacidosis?
Mazer-Amirshahi, M. E., & Chen, E. H. (2008) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2008.07.023 · Cited by 33
Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies
Duckworth, W. C., & Davis, S. N. (2007) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2007.01.001 · Cited by 33
Management of Diabetic Ketoacidosis in Children and Adolescents
Sherry, N., & Levitsky, L. L. (2008) · Pediatric Drugs · doi:10.2165/00148581-200810040-00002 · Cited by 33
Soluble insulin analogs combining rapid- and long-acting hypoglycemic properties – From an efficient E. coli expression system to a pharmaceutical formulation
Mikiewicz, D., Bierczyńska-Krzysik, A., Sobolewska, A., Stadnik, D., Bogiel, M., Pawłowska, M., Wójtowicz-Krawiec, A., Baran, P., Łukasiewicz, N., Romanik-Chruścielewska, A., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0172600 · Cited by 32
Progress in Simulation Studies of Insulin Structure and Function
Gorai, B., & Vashisth, H. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.908724 · Cited by 35
Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study
Dornhorst, A., Lüddeke, H.-J., Honka, M., Ackermann, R. W., Merilainen, M. J., Gallwitz, B., & Sreenan, S. (2007) · Current Medical Research and Opinion · doi:10.1185/030079908x260835 · Cited by 29
Development and Assessment of a Mobile Health Application for Monitoring the Linkage Among Treatment Factors of Type 1 Diabetes Mellitus
Bellei, E. A., Biduski, D., Lisboa, H. R. K., & Marchi, A. C. B. D. (2019) · Telemedicine Journal and e-Health · doi:10.1089/tmj.2018.0329 · Cited by 35
Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis
Tunis, S. L., Minshall, M. E., Conner, C., McCormick, J. I., Kapor, J., Yale, J., & Groleau, D. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990902869169 · Cited by 31
Contribution of TyrB26 to the Function and Stability of Insulin
Pandyarajan, V., Phillips, N. B., Rege, N. K., Lawrence, M. C., Whittaker, J., & Weiss, M. A. (2016) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.708347 · Cited by 31
New Insulin Analogues and Routes of Delivery
Roach, P. J. (2008) · Clinical Pharmacokinetics · doi:10.2165/00003088-200847090-00003 · Cited by 31

Authors: Hirsch, I. B.
Affiliations: University of Washington (US)
Corresponding author: Hirsch, Irl B.
ORCID: Hirsch, Irl B.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2005-01-13
Volume: 352
Issue: 2
Pages: 174-183
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmra040832
OpenAlex: W4242554702
Cited by: 667
References: 62
Citations by year: 2026: 13 · 2025: 8 · 2024: 14 · 2023: 11 · 2022: 23 · 2021: 16 · 2020: 26 · 2019: 19 · 2018: 31 · 2017: 29 · 2016: 36 · 2015: 36 · 2014: 27 · 2013: 39 · 2012: 46
FWCI: 5.86
Type: journal article
Language: en
Open access: closed
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords: insulin analogues, glycemic control, diabetes mellitus, hypoglycemia risk, insulin formulations
MeSH terms: Insulin Glargine, Child, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Drug Administration Schedule, Female, Humans, Hypoglycemic Agents, Insulin, Pregnancy, Blood Glucose Self-Monitoring, Insulin, Long-Acting, Insulin Aspart, Insulin Lispro

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Insulin Analogues

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks